• Micro- and Nanoplastics Drive Pulmonary Fibrosis via FXR-YAP

  2026-05-07

  This study provides systematic evidence that inhaled microplastics and nanoplastics, especially polystyrene nanoplastics, induce pulmonary fibrosis by disrupting the FXR-YAP1 signaling axis. Findings highlight the size- and polymer-dependent toxicity of emerging plastic pollutants, offering mechanistic insights for respiratory risk assessment.

• Bufalin Targets STK33: Mechanistic Advances in TNBC Research

  2026-05-06

  This study identifies Serine/Threonine Kinase 33 (STK33) as a novel and actionable target of the cardiotonic steroid Bufalin in triple-negative breast cancer (TNBC). Through multi-platform binding and degradation assays, the authors reveal how Bufalin disrupts STK33 stability, offering mechanistic and translational insights for future TNBC therapies.

• Affinity-Purified Goat Anti-Rabbit IgG (H+L): Mechanisms & A

  2026-05-06

  Discover the science behind Affinity-Purified Goat Anti-Rabbit IgG (H+L), a horseradish peroxidase conjugated secondary antibody. This article uniquely explores its molecular mechanism, practical assay optimization, and lessons from recent apoptosis research for advanced immunoassays.

• Halazone: Molecular Mechanisms and Precision Disinfection Sc

  2026-05-05

  Explore Halazone as a cutting-edge antimicrobial sulfonamide derivative, with a deep dive into its molecular mechanisms, stability, and advanced applications in water disinfection and neurophysiology. Uncover new insights for assay optimization and experimental design.

• Unlocking Translational Precision: HyperFluor™ 488 in Immune

  2026-05-05

  This thought-leadership article explores how the HyperFluor™ 488 Goat Anti-Human IgG (H+L) Antibody advances immunoassay sensitivity, reproducibility, and mechanistic insight for translational researchers. By weaving together mechanistic rationale, recent breakthroughs in mRNA vaccine development, and rigorous workflow optimization, we articulate clear strategic guidance for leveraging advanced fluorescent secondary antibodies in next-generation immunodetection, and clarify how this approach bridges preclinical innovation and real-world diagnostic needs.

• Wnt/β-catenin Inhibition Fails to Alleviate DSS-Induced Coli

  2026-05-04

  This study rigorously tested the therapeutic value of XAV939, a Wnt/β-catenin pathway inhibitor, in a dextran sulfate sodium-induced ulcerative colitis (UC) mouse model. Despite effectively suppressing Wnt/β-catenin signaling and SOX9 expression, XAV939 did not reduce intestinal inflammation or restore key epithelial markers, suggesting that this pathway is not the predominant driver of inflammation in this UC model.

• Dabigatran Etexilate: Innovations in Oral Anticoagulation fo

  2026-05-04

  This article reviews the clinical and pharmacological advances of dabigatran etexilate, the first oral direct thrombin inhibitor approved for stroke and venous thromboembolism prevention. The reference study highlights its predictable anticoagulant profile, favorable safety, and oral administration as significant improvements over traditional agents.

• XPO1 Inhibition by Eltanexor Modulates Wnt/β-catenin in CRC

  2026-05-03

  This study demonstrates that Eltanexor (KPT-8602), a second-generation XPO1 inhibitor, effectively reduces colorectal cancer tumorigenesis by modulating the Wnt/β-catenin signaling pathway. The findings provide mechanistic insight into Eltanexor’s chemopreventive potential and suggest practical parameters for preclinical research.

• DMH-1: Precision ALK2 Inhibition for Organoids & NSCLC Model

  2026-05-02

  This thought-leadership article explores how DMH-1, a highly selective ALK2 inhibitor from APExBIO, is reshaping translational research by enabling precise modulation of BMP signaling. By bridging recent advances in organoid technology and non-small cell lung cancer (NSCLC) models, we integrate mechanistic insights, experimental validation, and strategic guidance for researchers seeking to harness DMH-1’s unique properties. Drawing from the latest organoid studies and competitive benchmarking, we highlight how DMH-1 empowers high-fidelity modeling of cellular fate decisions and antitumor mechanisms—while providing actionable parameters and a visionary outlook on future applications.

• SIRT1/2 Inhibitor IV (cambinol): Protocols & Innovations

  2026-05-01

  SIRT1/2 Inhibitor IV (cambinol) empowers researchers to dissect SIRT1- and SIRT2-regulated pathways in CNS injury and cancer models with precision. Explore practical workflows, troubleshooting strategies, and new insights from lactylation-driven astrocyte polarization studies.

• Moxidectin Potentiates Polyenes via Ergosterol Elevation in

  2026-05-01

  A 2024 study reveals that moxidectin, widely known as a macrocyclic lactone anthelmintic, can elevate ergosterol biosynthesis in Candida albicans, thereby synergizing with polyene antifungals such as amphotericin B and nystatin. This mechanistic insight holds potential for more effective oral candidiasis therapies, particularly in drug-resistant or high-risk populations.

• Dextran Sulfate Sodium Salt: Precision in IBD Mouse Models

  2026-04-30

  Dextran sulfate sodium salt (MW 35000-45000) empowers researchers to create reproducible and mechanistically faithful mouse models of ulcerative colitis. This article details advanced workflows, protocol optimization, and troubleshooting strategies, grounded in the latest epithelial repair circuitry insights and bench-to-clinic translation.

• Gallein: Precision G Protein βγ Subunit Inhibitor in GPCR Re

  2026-04-30

  Gallein, a highly selective G protein βγ subunit inhibitor from APExBIO, empowers researchers to dissect GPCR signaling in cancer, immune modulation, and cardiometabolic models with robust reproducibility. Leveraging recent insights into insulin-independent glucose uptake and macrophage polarization, Gallein unlocks new frontiers in experimental design and translational workflows.

• KU-55933: Precision ATM Kinase Inhibition for DNA Damage Ass

  2026-04-29

  KU-55933 stands out as a potent ATM kinase inhibitor, enabling highly selective dissection of DNA damage response and cell cycle regulation. This guide delivers actionable protocols, advanced use-cases, and troubleshooting strategies to maximize experimental reproducibility and scientific impact.

• Renal Vascular Reactivity in Sepsis: Potassium Channel Block

  2026-04-29

  This study dissects how ATP-sensitive and calcium-activated potassium channel blockers modulate renal blood flow responses to vasoactive agents in septic rats. The findings reveal complex, potentially harmful interactions between K+ channel inhibition and vasopressor administration, with direct implications for experimental models of septic acute kidney injury.

16359 records 1/1091 page Next 12345 下5页 Last page